Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Invest New Drugs. 2014 Jun 1;32(6):1181–1187. doi: 10.1007/s10637-014-0121-6

Table 1.

Patient demographics and baseline characteristics

N = 24
Median age, years (range) 57 (34–81)
Male, n (%) 15 (63)
ECOG performance status
  0 4 (17)
  1 20 (83)
Race, n (%)
  White 18 (75)
  Black or African American 3 (13)
  Asian 2 (8)
  Not reported 1 (4)
Tumor types, n (%)
  Sarcoma 6 (25)
  Colorectal 4 (17)
  Pancreatic, ovarian, and liver 2 each
  SCLC, NSCLC, bladder, gallbladder, and gastric 1 each
  Other* 3 (13)

ECOG Eastern Coorperative Oncology Group; NSCLC non-small cell lung carcinoma; SCLC small-cell lung carcinoma

*

Cholangiocarcinoma, n = 2; metastatic neuroendocrine, n = 1